The Institute of Nuclear Medicine and Allied Sciences (Inmas) in collaboration with Dr Reddy’s Laboratories, Hyderabad, developed an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG). The third phase of the clinical trial results has shown that this molecule helps in the faster recovery of hospitalized patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in patients infected with the coronavirus.